Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Telmisartan,Amlodipine,Indapamide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
George Medicines Files NDA with FDA for Triple Combination Therapy for Hypertension
Details : GMRx2 is a triple combination of telmisartan, amlodipine and indapamide, in Phase III development for hypertension and for the prevention of recurrent intracerebral haemorrhage.
Brand Name : GMRx2
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 06, 2024
Lead Product(s) : Telmisartan,Amlodipine,Indapamide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Telmisartan,Amlodipine,Indapamide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GMRx2 is a single-pill, multi-mechanism, triple combination of telmisartan, amlodipine and indapamide, in novel and proprietary dosage strengths and is in Phase III development for hypertension and for the prevention of recurrent intracerebral haemorrhag...
Brand Name : GMRx2
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 12, 2023
Lead Product(s) : Telmisartan,Amlodipine,Indapamide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Telmisartan,Amlodipine,Indapamide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GMRx2 is George Medicine’s most advanced candidate in late-stage development. A single-pill triple combination, it contains low doses of the commonly used hypertension medications telmisartan, amlodipine and indapamide.
Brand Name : GMRx2
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 07, 2022
Lead Product(s) : Telmisartan,Amlodipine,Indapamide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Metformin,Dapagliflozin,Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : CUREator
Deal Size : $1.0 million
Deal Type : Financing
Details : GMRx4 is being developed to provide a synergistic effect from three best-in-class type 2 diabetes treatments – metformin, dapagliflozin and sitagliptin – and, in an ultra-low-dose, single pill formulation, aims to be a more effective, simpler and saf...
Brand Name : GMRx4
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 20, 2022
Lead Product(s) : Metformin,Dapagliflozin,Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : CUREator
Deal Size : $1.0 million
Deal Type : Financing
Lead Product(s) : Telmisartan,Amlodipine,Indapamide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GMRx2 is a single pill triple combination in novel and proprietary dosage strengths containing telmisartan, amlodipine and indapamide, targeted for first line therapy to control hypertension.
Brand Name : GMRx2
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 01, 2021
Lead Product(s) : Telmisartan,Amlodipine,Indapamide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?